Biotech company 10x Genomics (NASDAQ:TXG) will be announcing earnings results tomorrow after the bell. Here’s what investors ...

Genomics (TXG) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

10x Genomics (TXG) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #1 (Strong Buy). This rating change essentially reflects an upward trend in earnings ...

Wall Street analysts expect 10x Genomics (TXG) to post quarterly loss of $0.32 per share in its upcoming report, which indicates a year-over-year increase of 22%. Revenues are expected to be $158. ...

Shares of TXG opened at $7.14 on Tuesday. 10x Genomics has a 1 year low of $6.78 and a 1 year high of $37.74. The stock’s fifty day moving average price is $10.96 and its two-hundred day moving ...

Short interest in 10x Genomics Inc (NASDAQ:TXG) increased during the last reporting period, rising from 12.06M to 12.86M. This put 17.73% of the company's publicly available shares short.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...